Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Omega-3-fatty acids
Drug ID BADD_D01613
Description Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish). Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids. Therapeutic products containing omega-3 fatty acid and its derivatives for treatment of hypertriglyceridemia include Lovaza, Omtryg, Epanova, and Vascepa.
Indications and Usage Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia.
Marketing Status approved; nutraceutical
ATC Code Not Available
DrugBank ID DB11133
KEGG ID Not Available
MeSH ID D015525
PubChem ID 56842239
TTD Drug ID Not Available
NDC Product Code Not Available
UNII Not Available
Synonyms Fatty Acids, Omega-3 | Omega-3 Fatty Acid | Acid, Omega-3 Fatty | Fatty Acid, Omega-3 | Omega 3 Fatty Acid | Omega-3 Fatty Acids | n-3 Oil | Oil, n-3 | n 3 Oil | n3 Oil | Oil, n3 | n-3 Fatty Acids | n 3 Fatty Acids | Omega 3 Fatty Acids | n-3 PUFA | PUFA, n-3 | n 3 PUFA | n3 Fatty Acid | Fatty Acid, n3 | n3 PUFA | PUFA, n3 | n3 Polyunsaturated Fatty Acid | n3 Oils | n-3 Oils | n 3 Oils | N-3 Fatty Acid | Acid, N-3 Fatty | Fatty Acid, N-3 | N 3 Fatty Acid | n-3 Polyunsaturated Fatty Acid | n 3 Polyunsaturated Fatty Acid
Chemical Information
Molecular Formula C60H92O6
CAS Registry Number 329042-31-1
SMILES CCC=CCC=CCC=CCCCCCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CC C=CCCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase increased13.03.04.005--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Aspartate aminotransferase increased13.03.04.011--
Constipation07.02.02.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Eructation07.01.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Haemorrhagic disorder24.07.01.021; 01.01.03.004--Not Available
Headache17.14.01.001--
Nausea07.01.07.001--
Paraesthesia23.03.03.094; 17.02.06.005--
Polycythaemia vera01.13.03.002; 16.21.03.003--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Swelling08.01.03.015--Not Available
Vomiting07.01.07.003--
Malnutrition14.03.02.004--Not Available
Sensitisation10.02.01.012; 08.01.05.009--Not Available
The 1th Page    1    Total 1 Pages